Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung

American Journal of Translational Research

Volumn 2, Issue 3, 2010, Pages 309-315

  McIntire, Maria G ^a   Santagata, Sandro ^a   Ligon, Keith ^a   Chirieac, Lucian R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chromogenic in situ hybridization; Copy number; EGFR; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PARAFFIN; PEROXIDASE;

ADULT; AGED; ARTICLE; ATYPICAL ADENOMATOUS HYPERPLASIA; CANCER INVASION; CELL NUCLEUS; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; MORPHOGENESIS; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 77954662171     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Sharma SV, Bell DW, Settleman J and Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
3. Testa JR and Siegfried JM. Chromosome abnormalities in human non-small cell lung cancer. Cancer Res 1992; 52: 2702s-2706s.
4. Westra WH. Early glandular neoplasia of the lung. Respir Res 2000; 1: 163-169.
5. Beasley MB, Brambilla E and Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005; 40: 90-97.
6. Kerr KM. Pulmonary preinvasive neoplasia. J Clin Pathol 2001; 54: 257-271.
7. Chiosea S, Jelezcova E, Chandran U, Luo J, Mantha G, Sobol RW and Dacic S. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res 2007; 67: 2345-2350.
8. Ikeda K, Nomori H, Ohba Y, Shibata H, Mori T, Honda Y, Iyama K and Kobayashi T. Epidermal growth factor receptor mutations in multicentric lung adenocarcinomas and atypical adenomatous hyperplasias. J Thorac Oncol 2008; 3: 467-471.
9. Wu M, Orta L, Gil J, Li G, Hu A and Burstein DE. Immunohistochemical detection of XIAP and p63 in adenomatous hyperplasia, atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and well-differentiated adenocarcinoma. Mod Pathol 2008; 21: 553-558.
10. Licchesi JD, Westra WH, Hooker CM, Machida EO, Baylin SB and Herman JG. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008; 29: 895-904.
11. Sartori G, Cavazza A, Bertolini F, Longo L, Marchioni A, Costantini M, Barbieri F, Migaldi M and Rossi G. A subset of lung adenocarcinomas and atypical adenomatous hyperplasiaassociated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis. Am J Clin Pathol 2008; 129: 202-210.
12. Licchesi JD, Westra WH, Hooker CM and Herman JG. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 2008; 14: 2570-2578.
13. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ and Taron M. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
14. Herbst RS, Heymach JV and Lippman SM. Lung cancer. N Engl J Med 2008; 359: 1367-1380.
15. Sholl LM, John Iafrate A, Chou YP, Wu MT, Goan YG, Su L, Huang YT, Christiani DC and Chirieac LR. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol 2007; 20: 1028-1035.
16. Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Janne PA, Christiani DC and Chirieac LR. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res 2009; 69: 8341-8348.
17. Awaya H, Takeshima Y, Furonaka O, Kohno N and Inai K. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol 2005; 58: 1076-1080.
18. Gallegos Ruiz MI, Floor K, Vos W, Grunberg K, Meijer GA, Rodriguez JA and Giaccone G. Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization. Histopathology 2007; 51: 631-637.
19. Yoo SB, Lee HJ, Park JO, Choe G, Chung DH, Seo JW and Chung JH. Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in nonsmallcell lung carcinomas: A comparison with fluorescence in situ hybridization study. Lung Cancer 2009
20. Gong Y, Gilcrease M and Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol 2005; 18: 1015-1021.
21. Hanna WM and Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol 2006; 19: 481-487.
22. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ and Isola J. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/ neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000; 157: 1467-1472.
23. Travis WD BE, Muller-Hermelink HK, et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus, and Heart. World Health Organization Classification of Tumours. Lyon: IARC Press, 2004.
24. Greene FL PD, Fleming ID, Fritz A. AJCC Cancer Staging Manual (6th Edition). New York: Springer-Verlag, 2002.
25. Thorner PS, Ho M, Chilton-MacNeill S and Zielenska M. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections. Am J Surg Pathol 2006; 30: 635-642.
26. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Nakayama H, Kameda Y, Tsuchiya E and Miyagi Y. Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. Mod Pathol 2007; 20: 967-973.
27. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Noda K, Nakayama H, Kameda Y, Tsuchiya E and Miyagi Y. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol 2007; 128: 100-108.
28. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR and Tsai SF. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10: 8195-8203.
29. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba, II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD and Gazdar AF. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
30. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, Tabata M, Ueoka H, Tanimoto M, Date H, Gazdar AF and Shimizu N. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in nonsmall cell lung cancers. Clin Cancer Res 2005; 11: 1167-1173.
31. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Jr. and Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
32. Cappuzzo F, Ligorio C, Janne PA, Toschi L, Rossi E, Trisolini R, Paioli D, Holmes AJ, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Ciardiello F, Patelli M, Crino L and Varella-Garcia M. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridizationpositive/phospho-Akt-positive or never smoker patients with advanced non-smallcell lung cancer: the ONCOBELL trial. J Clin Oncol 2007; 25: 2248-2255.
33. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N and Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034-5042.
34. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA, Jr., Franklin WA, Crowley J and Gandara DR. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005; 23: 6838-6845.